Home Tags BioAtla

Tag: BioAtla

Phase I/II Trial with CAB-ROR2-ADC Doses First Patient

In late June a first patient was been dosed in a clinical trial BA3021-001 with BioAtla's BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate...

FDA Clears Investigational New Drug application for BA3011, a Novel CAB-AXL-ADC...

The U.S. Food and Drug Administration has cleared the Investigational New Drug Application (IND) for BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC)...